Teleflex Analyst Ratings
Truist Raises Price Target on Teleflex to $240 From $235, Maintains Hold Rating
Teleflex Analyst Ratings
Piper Upgrades Teleflex to Overweight, Cites Expected EPS Growth
Teleflex Analyst Ratings
RBC Cuts Price Target on Teleflex to $235 From $255, Maintains Outperform Rating
Teleflex's Strong Market Position and Growth Opportunities Amidst Competitor Challenges: A Buy Rating Endorsement
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Xtant Medical Holdings (XTNT), Teleflex (TFX) and Esperion (ESPR)
Teleflex (TFX) Receives a Hold From Piper Sandler
Truist Financial Sticks to Their Hold Rating for Teleflex (TFX)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)
Wells Fargo Sticks to Its Hold Rating for Teleflex (TFX)
Teleflex (TFX) Gets a Buy From RBC Capital
RBC Capital Adjusts Price Target on Teleflex to $255 From $265
Teleflex Analyst Ratings
Needham Sticks to Their Hold Rating for Teleflex (TFX)
Wells Fargo Cuts Price Target on Teleflex to $210 From $265
RBC Capital Sticks to Its Buy Rating for Teleflex (TFX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN)